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is further confused because DVT may be subclinical,
patients may confuse superficial thrombophlebitis with
DVT when giving a history, and duplex ultrasound scan-
ning is less sensitive than venography in the detection of
minor postthrombotic changes.
On theoretic grounds, it seems plausible to hypothe-
size that postthrombotic CVU in the presence of throm-
bophilia may be more severe because the thrombosis is
likely to be recurrent, more extensive, and, possibly, more
resistant to both treatment and endogenous fibrinolysis
and recanalization. If a clear relationship between a pro-
portion of CVU and certain thrombophilias could be
shown, new preventative and treatment opportunities
might open up. The aim of this study, therefore, was to
determine the prevalence of thrombophilia in CVU and to
examine, for the first time, whether thrombophilia is asso-
ciated with a history and or duplex scan evidence of DVT
and clinical severity of chronic venous disease.
METHODS
Clinical and duplex scan assessment. This study was
approved as part of a larger study by the local ethical com-
mittee board. Informed, signed consent was obtained
from all patients before investigation. Patients seen at a
hospital-based, “one-stop,” leg ulcer clinic with ulcerated
limbs underwent history and physical examination and mea-
surement of ankle-brachial pressure index. Note was made
of previous major trauma, major surgery (including ortho-
pedic), obesity (with body mass index), and use of the
In the United Kingdom, the life-time risk of develop-
ment of chronic venous ulceration (CVU) is 1%,1 and the
annual cost of treatment is estimated at approximately
,£600 million ($1 billion), which constitutes 1% to 2%
of total healthcare spending.2 Similar figures pertain
in other European countries and in North America.3
Thrombophilia is increasingly recognized as a risk factor
for deep venous thrombosis (DVT), which in turn is a
major risk factor for chronic venous insufficiency and
CVU.4 Specifically, the available literature suggests that
between 25% and 75% of patients with CVU have post-
thrombotic disease on the basis of a history of DVT or evi-
dence of postphlebitic changes in the deep venous system
on investigation.5 However, these estimates vary widely
according to the population studied and the thoroughness
with which history and investigative evidence of prior
DVT are sought. The association between CVU and DVT
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Background: Thrombophilia is increasingly recognized as a risk factor for deep venous thrombosis (DVT), which in turn
is a major risk factor for chronic venous ulceration (CVU). However, the relationship between thrombophilia and CVU
remains unknown. The aim of this study was to define the prevalence of thrombophilia in patients with CVU and to
determine whether this is associated with a history or duplex scan evidence of DVT.
Methods: Eighty-eight patients with CVU were prospectively studied. The patients underwent clinical assessment and
duplex ultrasound scanning. Blood was drawn for antithrombin, proteins C and S, activated protein C resistance, fac-
tor V Leiden, prothrombin 20210A, lupus anticoagulant, and anticardiolipin antibodies.
Results: The study included 35 men with a median age of 61 years (interquartile range, 45 to 72 years) and 53 women
with a median age of 76 years (interquartile range, 69 to 82 years). Thirty-six percent of the patients had either a his-
tory or duplex scan evidence suggestive of previous DVT. The following abnormalities were detected: four, five, and
six cases of antithrombin, protein C, and protein S deficiencies, respectively; 14 cases of activated protein C resistance;
11 cases of factor V Leiden mutation; three cases of prothrombin 20210A mutation; eight cases of lupus anticoagu-
lant; and 12 cases of anticardiolipin antibodies. Thrombophilia was not significantly related to previous DVT, deep
reflux, or disease severity.
Conclusion: Patients with CVU have a 41% prevalence rate of thrombophilia. This rate is two to 30 times higher than
the rate of the general population but is similar to that reported for patients with previous DVT. However, in patients
with CVU, thrombophilia does not appear to be related to a history of DVT, a pattern of reflux, or severity of disease.
Many patients with CVU may have unsuspected postthrombotic disease. (J Vasc Surg 2002;35:718-22.)
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contraceptive pill. Venous duplex ultrasonography (HDI
5000, Advanced Technology Laboratories, Bothell, Wash)
of the ulcerated leg(s) was performed by a single observer
(RKM). Nonulcerated limbs did not undergo duplex scan-
ning because of time restrictions. The patients were exam-
ined in reverse Trendelenburg position at an angle of 45
degrees on a tilting couch. The following veins were
examined: proximal and distal super- ficial femoral,
above-knee and below-knee popliteal, posterior tibial, per-
oneal, saphenofemoral and saphenopopliteal junctions,
above-knee and below-knee long saphenous, short saphe-
nous, and gastrocnemius/soleal. Reflux was induced with
a manual calf squeeze and was considered to be signifi-
cant if it exceeded 0.5 seconds.6,7 Post-thrombotic fea-
tures, such as deep vein obstruction, partial recanalization,
vein wall irregularity, or valve cusp thickening, were noted.
Deep venous reflux (DVR) was defined as significant reflux
in the popliteal or superficial femoral vein. A history of
DVT was taken from clinical records and from patient rec-
ollection of limb swelling, pain, or “white leg.” CVU was
diagnosed on the basis of venous reflux on duplex scan
results and exclusion of other causes. No patient had a his-
tory of DVT less than 1 year before the clinic appointment.
Thrombophilia testing. A standard thrombophilia
screen was performed that examined the congenital con-
ditions of antithrombin, protein C, and protein S defi-
ciency and factor V Leiden and prothrombin 20210A
mutations. The acquired antiphospholipid antibodies (see
subsequent) were also assayed. Venous blood was drawn
into 3.8% trisodium citrate (1:9 volume) for throm-
bophilia investigations. The following tests were per-
formed: antithrombin activity (Dade Behring [Deerfield,
Ill], healthy range, 0.8 to 1.20 IU/mL), protein C
(Chromatic Chromogenix [Mölndal, Sweden], healthy
range, 0.67 to 1.38 IU/mL), protein S (healthy range,
free 0.61 to 1.43 and total 0.64 to 1.54 IU/mL), acti-
vated protein C resistance (Coatest Chromogenix
[Mölndal, Sweden], healthy range, >2.0), factor V Leiden
and prothrombin 20210A with Multiplex allele-specific
amplification polymerase chain reaction (MJ Research,
Inc, Waltham, Mass), and the antiphospholipid antibodies
(lupus anticoagulant; Diagen [Diagnostic Reagents Ltd,
Thane, Oxon, UK], healthy range, >1.09:1) and anticar-
diolipin antibodies (Organon Technika [Rochville, Md],
healthy range, immunoglobulin G < 13 G units/mL and
immunoglobulin M < 10 M units/mL). All patients in
Table I. Relationship between history of deep venous
thrombosis, duplex scan evidence of previous deep
venous thrombosis, and deep venous reflux
Duplex scan evidence of previous DVT
History of DVT Yes No
Yes 19 (19) 10 (5)
No 3 (3) 56 (26)
Numbers in brackets are those patients with deep venous reflux in at
least the popliteal segment. 
DVT, Deep venous thrombosis.
Table II. Demographics of patients with and without
abnormal thrombophilia screen results
No P
thrombophilia Thrombophilia value
All patients
No. of patients 52 36
Male:female ratio (%) 50:50 25:75 .029†
Median age 69 77 .005‡
(IQR; years) (56-76) (65-87)
Median age at first ulcer 54 66 .029‡
(40-66) (45-83)
Previous DVT 33% 42% NS†
Patients after exclusion*
No. of patients 64 24
Male:female ratio (%) 50:50 33:67 NS†
Median age 70 75 NS‡
(IQR; years) (56-77) (65-85)
Median age at first ulcer 56 62 NS‡
(IQR; years) (40-68) (37-81)
Previous DVT 36% 38% NS†
*After exclusion of those patients with isolated antiphospholipid anti-
bodies.
†P value determined with 2 test.
‡P value determined with Mann-Whitney test.
IQR, Interquartile range; NS, not significant; DVT, deep venous throm-
bosis.
Fig 1. Prevalence of thrombophilia in patients with chronic
venous ulceration.
AT, Antithrombin deficiency; PC, protein C deficiency; PS, pro-
tein S deficiency; APCR, activated protein C resistance; fVL, fac-
tor V Leiden; fIIL, (prothrombin 20210A) factor II Leiden; LA,
lupus anticoagulant; ACLA, anticardiolipin antibody.
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whom an abnormality was detected (ie, less than healthy
range for antithrombin, protein C, protein S, and activated
protein C resistance or more than healthy levels for the
antiphospholipid antibodies) were asked to return for
repeat thrombophilia screen after a minimum of 3 months.
Only patients with abnormalities on both occasions were
considered to have a thrombophilia.
Statistical methods. SPSS version 10.0.5 package
(Statistical Package for Social Sciences Inc, Chicago, Ill)
was used for all statistical analysis. For categoric data, 2
test or Kruskal-Wallis test were applied, and for continu-
ous variables, the Mann-Whitney test was used.
Exclusions. Six patients who were already undergoing
oral anticoagulation therapy were excluded because of the
known interference of warfarin with thrombophilia test-
ing. One patient was excluded on the basis of having a
thrombophilic abnormality on only one occasion. Two
patients refused blood sampling.
RESULTS
Patients. This was a prospective study of 97 consecu-
tive patients with CVU who attended a hospital-based leg
ulcer clinic. Nine patients were excluded for the reasons
shown previously, which left 88 patients in the study
group. There were 35 men with a median age of 61 years
(interquartile range, 45 to 72 years) and 53 women with
a median age of 76 years (interquartile range, 69 to 82
years; P = .001). Twelve men (34%) and 20 women (38%)
gave a history of ipsilateral lower limb DVT.
Duplex scan findings. There was only a weak relation-
ship between a history of DVT and evidence of previous
DVT on duplex scan results, although a history of DVT
was strongly associated with DVR (P < .001; Table I).
Thus, of the 29 patients who gave a history of DVT, only
19 (66%) had evidence of previous DVT on duplex scan
results, although 24 of 29 (83%) had DVR. A further
three patients had evidence of previous DVT on scan
results but were unaware they had had a DVT and had no
record of this in their hospital notes.
Thrombophilia. Overall, 36 of 88 patients (41%) had at
least one abnormality on thrombophilia test results (Fig 1;
Table II). The significance of the presence of antiphospho-
lipid antibodies alone is less certain8 than the other factors in
terms of causing venous thromboembolism, and the condi-
tion is fairly common in the population, particularly among
older women. If isolated antiphospholipid antibodies are
excluded from the overall analysis results, there was no age or
gender difference between those patients with and without
Table III. Severity of disease in patients with and without thrombophilia
Median values (IQR) No thrombophilia (n = 52) Thrombophilia (n = 36) P value
Total ulcer disease duration (months) 78 (24-234) 48 (16-240) NS*
Duration of this episode (months) 6 (2-24) 10 (3-18) NS*
Total area (cm2) 3.8 (0.1-9.5) 2.9 (1.8-12) NS*
No. of episodes 2 (1-5) 2 (1-5) NS†
Level of pain (0-3) 2 (1-3) 2 (0-3) NS†
*P value determined with Mann Whitney test.
†P value determined with 2 test.
IQR, Interquartile range; NS, not significant.
Fig 2. Number of patients with multiple thrombophilic tendencies.
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thrombophilia (Table II). Thrombophilia was not related to
the clinical severity of the ulcer disease (ie, duration of dis-
ease, total area, number of episodes, or level of pain; Table
III), previous history of DVT (Table IV), duplex scan evi-
dence of DVT (apart from antithrombin and anticardiolipin
antibodies; Table V), or the pattern of deep and superficial
reflux (Table VI). No pattern to the position of ulceration or
lipodermatosclerosis was identified between the groups. One
patient gave a family history of DVT, but affected family
members had not undergone testing for thrombophilia.
There was no association between the number of throm-
bophilic abnormalities and the severity of disease or the pat-
tern or severity of reflux (Fig 2). Interestingly, the patient
with five abnormalities had no history of DVT and no evi-
dence of deep venous disease. A history of trauma, major
surgery (including orthopedic), cancer, obesity (body mass
index >25), and use of the contraceptive pill did not increase
the prevalence of DVT in patients with thrombophilia.
DISCUSSION
The principal finding of this study is that more than
40% of patients with CVU seen at a hospital-based leg
ulcer clinic have at least one identifiable thrombophilia.
This rate is two to 30 times higher than the rate in the
general population but similar to that reported for patients
with DVT (Table VII). Given that DVT is the single most
common identifiable risk factor for the development of
CVU and that patients with postthrombotic disease have a
significantly worse prognosis in response to medical9 and
surgical therapy,10,11 it is perhaps surprising that little
information exists regarding the relationship between
thrombophilia and CVU. The studies that do exist are
small and often methodologically flawed and give a con-
flicting picture with regard to the relationship between
thrombophilia and a clinical history of DVT. Munkvad
and Jorgensen,12 Ribeaudeau et al,13 Alcaraz et al,14 and
Hafner and Felten15 found that, in patients with CVU,
there was no difference in DVT rates between those with
and without thrombophilia. By contrast, Maessen-Visch et
al16 found that in patients with CVU, 91% of patients with
positive results for factor V Leiden gave a history of DVT
as compared with 48% of those without the mutation.
Table IV. Prevalence of thrombophilia in patients with
and without a history of ipsilateral deep venous throm-
bosis
History No history  P
of DVT of DVT value*
Antithrombin deficiency 3 (10%) 1 (2%) NS
Protein C deficiency 2 (7%) 3 (5%) NS
Protein S deficiency 3 (10%) 3 (5%) NS
Activated protein C resistance 5 (17%) 9 (15%) NS
Factor V Leiden 1 (3%) 2 (3%) NS
Prothrombin G20210A 4 (14%) 7 (12%) NS
Lupus anticoagulant 2 (7%) 6 (10%) NS
Anticardiolipin antibody 6 (20%) 6 (10%) NS
*P value determined with 2 test.
DVT, Deep venous thrombosis; NS, not significant.
Table V. Prevalence of thrombophilia in patients with
and without duplex scan evidence of previous ipsilateral
deep venous thrombosis
Median values Duplex scan No duplex scan P
(IQR) evidence of DVT evidence of DVT value*
Antithrombin deficiency 3 (14%) 1 (2%) .02
Protein C deficiency 2 (9%) 3 (5%) NS
Protein S deficiency 2 (9%) 4 (6%) NS
Activated protein C 5 (23%) 9 (14%) NS
resistance
Factor V Leiden 2 (9%) 1 (2%) NS
Prothrombin G20210A 3 (14%) 8 (12%) NS
Lupus anticoagulant 1 (5%) 7 (11%) NS
Anticardiolipin antibody 6 (27%) 6 (9%) .03
*P value determined with 2 test.
IQR, Interquartile range; DVT, deep venous thrombosis; NS, not signifi-
cant.
Table VI. Patterns of reflux (>0.5 seconds) in patients
with chronic venous ulceration with and without throm-
bophilia
No thrombophilia Thrombophilia P
(n = 52) (n = 36) value*
DVR only 4 (8%) 5 (14%) NS
SVR only 20 (38%) 11 (31%) NS
DVR and SVR 26 (50%) 19 (53%) NS
Any DVR 30 (58%) 24 (67%) NS
Any SVR 46 (88%) 30 (83%) NS
*P value determined with 2 test.
DVR, Deep venous reflux; SVR, superficial venous reflux; NS, not sig-
nificant.
Table VII. Prevalence of specific thrombophilias in
patients with chronic venous ulceration, in patients with
first episode of venous thromboembolism, and in the
general population
Patients with Patients with first General 
CVU (n = 88) episode of VTE population
LA 8 (9%) 10% 2%
ACA 12 (14%) 20% 10%
Antithrombin 4 (5%) 1% 0.2%
PC 5 (6%) 3% 0.3%
PS 6 (7%) 5% 0.2%
APCR 14 (16%) 20% 6%
FVL 11 (13%) 18% 7%
Prothrombin 3 (4%) 6% 2%
20210A
First venous thromboembolism and general population prevalence figures
from world literature.8,17-26
CVU, Chronic venous ulceration; VTE, venous thromboembolism; LA,
lupus anticoagulant; ACA, anticardiolipin antibodies; PC, protein C; PS,
protein S; APCR, activated protein C resistance; FVL, factor V Leiden. 
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However, these patients did not all have documented
DVT and did not undergo investigation with venography
or duplex ultrasound scan.
Between 25% and 75% of patients with CVU are
thought to have sustained a previous DVT on the basis of
history or investigation.5 However, as present data con-
firm, a history of DVT is unreliable with both false posi-
tive and negative results. Furthermore, duplex scan is less
capable than venography, rarely performed these days in
the United Kingdom, in distinguishing postthrombotic
deep venous disease from deep primary valvular incompe-
tence. This is especially so in the veins of the calf.
Interestingly, in this study, there appeared to be no rela-
tionship between the presence of thrombophilia and the
severity of disease, pattern of reflux, history of DVT, or
duplex scan evidence of postthrombotic disease. Neither
specific coagulation defects nor the presence of a hyperco-
agulable state led to the worsening of ulcer duration, num-
ber of episodes of recurrence, total area of ulceration, or
pain from the ulcer. There was also no pattern to the loca-
tion of ulceration or lipodermatosclerosis between the
groups. Although, because of small numbers, one must cau-
tion against overinterpretation of the data, these observa-
tions do raise the intriguing possibility that many patients
with CVU in association with apparently isolated superfi-
cial, or superficial and limited deep disease, may have in fact
sustained distal macrovascular, or even microvascular,
thrombosis as a result of unrecognized thrombophilia. Such
disease may be below the threshold of detection for duplex
ultrasonography, even venography. The existence of such
unrecognized thrombosis in association with thrombophilia
might explain why some patients with gross superficial
reflux have pristine skin and others with lesser degrees of
superficial reflux and (near) healthy deep veins have skin
changes and, eventually, develop ulceration.
In conclusion, thrombophilia is increasingly recog-
nized as a major risk factor for DVT, which in turn is the
major risk factor for intractable CVU. More than 40% of
patients with CVU have at least one thrombophilia. The
association between thrombophilia and the development
of chronic venous insufficiency and ulceration needs fur-
ther elucidation through larger cross-sectional and longi-
tudinal studies.
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